3 December 2024
02 December 2024 Baker McKenzie Advises ATB Therapeutics on EUR 54 million Series A Financing
Advising firms
Deal team
1 lawyer named| Lawyer | Firm | Seniority | Practice | Office |
|---|---|---|---|---|
| Younes Sebbarh Lead | Baker McKenzie | Not stated | corporate/M&A and life sciences | Not stated |
Want co-counsel patterns, repeat clients and alerts when these firms land their next deal? Get Pro.
Stated terms
- Stated value
- EUR 54m (EUR 54 million)
- What the figure measures
- Fund size
- Client
- ATB Therapeutics SAIssuer
- Counterparties
- EQT Life Sciences (Investor)
V-Bio Ventures (Investor)
Belgian Wealth Sovereign Fund SFPIM (Investor)
VIVES Partners (Investor)
Wallonie Entreprendre (Investor)
Sambrinvest (Investor)